Telo Genomics Corp. (TDSGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Telo Genomics Corp. (TDSGF) trades at $0.03. Telo Genomics Corp. is a biotech company focused on developing and commercializing predictive technological products for personalized treatment plans. Market cap: $3.20M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for TDSGF: TDSGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TDSGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TDSGF: 1/1 perspectives are bearish.
How is this calculated? →Telo Genomics Corp. (TDSGF) Healthcare & Pipeline Overview
Telo Genomics Corp. is a biotech company specializing in telomere analysis for personalized medicine, particularly in oncology and neurological diseases. Their Telo-MM solution targets Multiple Myeloma, offering diagnostic and prognostic applications to pathologists, clinicians, researchers, and drug developers within the healthcare sector.
What Is the Investment Thesis for TDSGF?
Telo Genomics Corp. presents a focused investment opportunity within the personalized medicine and diagnostics sector. The company's Telo-MM solution, targeting Multiple Myeloma, addresses a critical need for more precise and effective treatment strategies in oncology. A key value driver is the potential for Telo-MM to become a standard diagnostic tool, improving patient outcomes and driving revenue growth. The collaboration with the Mayo Clinic serves as a significant validation of the technology and could accelerate adoption. However, the company's small size and OTC listing introduce liquidity and regulatory risks. Success hinges on the successful commercialization of Telo-MM and expansion into other diagnostic applications. Key metrics to watch include adoption rates of Telo-MM, revenue growth, and progress in securing regulatory approvals.
Based on FMP financials and quantitative analysis
TDSGF Key Highlights
- Telo-MM is the lead application, providing actionable information for medical professionals in the treatment of Multiple Myeloma.
- Collaboration agreement with the Mayo Clinic to validate Telo-MM tests for multiple myeloma.
- TeloView is a proprietary software platform used to quantify specific features of each patient's telomeres.
- Focus on telomere analysis platform with diagnostic and prognostic applications.
- Serves pathologists, clinicians, academic researchers, and drug developers.
Who Are TDSGF's Competitors?
TDSGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ENZN Enzon Pharmaceuticals, Inc. | $4.35 | -8.42% | $28.76M | 42 |
| HLYK HealthLynked Corp. | $3.20 | -12.06% | $9.41M | 46 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TDSGF's Key Strengths?
- Proprietary telomere analysis technology.
- Collaboration with the Mayo Clinic.
- Focus on personalized medicine.
- Specialized Telo-MM solution for Multiple Myeloma.
What Are TDSGF's Weaknesses?
- Small company size and limited resources.
- OTC listing introduces liquidity and regulatory risks.
- Dependence on a single lead product (Telo-MM).
- Limited market presence and brand recognition.
What Could Drive TDSGF Stock Higher?
- Validation of Telo-MM tests for multiple myeloma through the collaboration with the Mayo Clinic.
- Potential expansion into new therapeutic areas beyond Multiple Myeloma.
- Potential strategic partnerships with pharmaceutical companies and research institutions.
- Geographic expansion into international markets.
- Development of advanced liquid biopsy technologies.
What Are the Key Risks for TDSGF?
- Financial-distress signal — its Altman Z-Score of -43.08 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from larger, more established diagnostic companies.
- Regulatory hurdles and approval delays.
- Technological obsolescence.
- Small company size and limited resources.
- OTC listing introduces liquidity and regulatory risks.
What Are the Growth Opportunities for TDSGF?
- Expansion into New Therapeutic Areas: Telo Genomics can leverage its telomere analysis platform to develop diagnostic and prognostic tools for other cancers and neurological disorders beyond Multiple Myeloma. This expansion would significantly increase the company's addressable market, tapping into the broader oncology and neurology diagnostics market, estimated to reach $80 billion by 2028. Success depends on demonstrating the applicability of telomere analysis across different disease types and securing regulatory approvals for new applications.
- Strategic Partnerships and Collaborations: Forming partnerships with pharmaceutical companies and research institutions can accelerate the development and commercialization of new diagnostic solutions. Collaborations can provide access to funding, expertise, and distribution channels, enhancing Telo Genomics' market reach and credibility. The existing collaboration with the Mayo Clinic serves as a model for future partnerships, potentially expanding into other leading medical centers and pharmaceutical firms.
- Geographic Expansion: Expanding into international markets, particularly Europe and Asia, represents a significant growth opportunity for Telo Genomics. These markets have a growing demand for advanced diagnostic tools and personalized medicine solutions. Entering new markets requires navigating different regulatory landscapes and establishing local partnerships. The global diagnostics market is projected to reach $115 billion by 2027, offering substantial opportunities for growth.
- Development of Liquid Biopsy Technologies: Further development and refinement of liquid biopsy technologies can enhance the accuracy and efficiency of Telo Genomics' diagnostic solutions. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, improving patient comfort and reducing healthcare costs. The liquid biopsy market is expected to reach $15 billion by 2025, driven by increasing demand for early cancer detection and personalized treatment monitoring.
- Integration of Artificial Intelligence and Machine Learning: Integrating AI and machine learning algorithms into the TeloView platform can enhance the analysis of telomere data and improve the accuracy of diagnostic predictions. AI-powered diagnostics can identify subtle patterns and correlations in telomere data that may be missed by human analysis, leading to more precise and personalized treatment recommendations. The market for AI in healthcare is projected to reach $34 billion by 2025, offering significant opportunities for innovation and growth.
What Opportunities Does TDSGF Have?
- Expansion into new therapeutic areas (other cancers, neurological diseases).
- Strategic partnerships with pharmaceutical companies and research institutions.
- Geographic expansion into international markets.
- Development of advanced liquid biopsy technologies.
What Threats Does TDSGF Face?
- Competition from larger, more established diagnostic companies.
- Regulatory hurdles and approval delays.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are TDSGF's Competitive Advantages?
- Proprietary Telomere Analysis Platform: Telo Genomics' unique technology for analyzing telomeres provides a competitive edge in the diagnostics market.
- Collaboration with Mayo Clinic: The partnership with a renowned institution like the Mayo Clinic enhances the credibility and validation of Telo Genomics' products.
- Focus on Personalized Medicine: The company's focus on personalized treatment plans aligns with the growing trend towards precision medicine in healthcare.
- Specialized Telo-MM Solution: The Telo-MM solution targets a specific unmet need in Multiple Myeloma treatment, creating a niche market.
What Does TDSGF Do?
Telo Genomics Corp., formerly known as 3D Signatures Inc., was incorporated in 2014 and rebranded in April 2019. Headquartered in Toronto, Canada, the company operates as a biotech firm focused on developing and commercializing predictive technological products designed to personalize treatment plans for patients with specific conditions. Telo Genomics' core offering revolves around its telomere analysis platform, which has diagnostic and prognostic applications, particularly in oncology and neurological diseases. Their solutions incorporate liquid biopsies and related technologies. The company's flagship product, Telo-MM, is designed to provide medical professionals with actionable insights for the treatment of Multiple Myeloma, a form of blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software platform that quantifies specific features of a patient's telomeres. Telo Genomics serves a diverse clientele, including pathologists, clinicians, academic researchers, and drug developers. The company has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma, enhancing its credibility and market reach.
What Products and Services Does TDSGF Offer?
- Develops telomere analysis platform for diagnostic and prognostic applications.
- Offers solutions with liquid biopsies and related technologies in oncology and neurological diseases.
- Provides Telo-MM, a solution for actionable information in the treatment of Multiple Myeloma.
- Offers TeloView, a proprietary software platform to quantify specific features of each patient's telomeres.
- Serves pathologists, clinicians, academic researchers, and drug developers.
- Collaborates with the Mayo Clinic to validate Telo-MM tests for multiple myeloma.
How Does TDSGF Make Money?
- Develops and commercializes diagnostic and prognostic tools based on telomere analysis.
- Generates revenue through the sale of Telo-MM and TeloView solutions.
- Partners with healthcare providers and research institutions to validate and promote its products.
- Seeks collaborations with pharmaceutical companies for drug development and clinical trials.
What Industry Does TDSGF Operate In?
Telo Genomics Corp. operates within the medical diagnostics and research industry, a segment experiencing growth due to advancements in personalized medicine and liquid biopsy technologies. The competitive landscape includes companies like CLABF (Colabora Biosciences Inc.), CTABF (Creative Medical Technology Holdings, Inc.), and ENZN (Enzon Pharmaceuticals, Inc.) that are also developing diagnostic and therapeutic solutions. The increasing prevalence of cancer and neurological diseases drives demand for innovative diagnostic tools. Telo Genomics aims to carve a niche by leveraging its telomere analysis platform to provide more precise and personalized treatment strategies.
Who Are TDSGF's Key Customers?
- Pathologists who use Telo Genomics' tools for disease diagnosis.
- Clinicians who use Telo Genomics' solutions to personalize treatment plans.
- Academic researchers who use Telo Genomics' platform for research purposes.
- Drug developers who use Telo Genomics' technology in clinical trials.
Company Profile
Telo Genomics Corp. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO John Allen Farlinger. TDSGF has traded publicly since 2021.
Telo Genomics Corp. (TDSGF) Valuation Context
Valued at $3.20M, TDSGF is classified as a micro-cap stock.
Key Financial Metrics
Its free cash flow yield is -33.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.49 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -51.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Telo Genomics Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -43.08 places it in the distress zone, a signal of elevated financial risk.
TDSGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary telomere analysis technology.
- Collaboration with the Mayo Clinic.
- Focus on personalized medicine.
- Specialized Telo-MM solution for Multiple Myeloma.
Bear Case
- Small company size and limited resources.
- OTC listing introduces liquidity and regulatory risks.
- Dependence on a single lead product (Telo-MM).
- Limited market presence and brand recognition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
TDSGF Latest News
No recent news available for TDSGF.
TDSGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TDSGF.
Price Targets
Wall Street price target analysis for TDSGF.
TDSGF MoonshotScore
What does this score mean?
The MoonshotScore rates TDSGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sabine Mai
CEO
Sabine Mai is the CEO of Telo Genomics Corp. Her background includes extensive experience in molecular biology and genetics. She has held various leadership positions in biotech companies, focusing on the development and commercialization of diagnostic and therapeutic products. Her expertise lies in translating scientific discoveries into clinical applications. She has a strong track record in securing funding, building strategic partnerships, and driving product development.
Track Record: Under Sabine Mai's leadership, Telo Genomics Corp. has focused on developing and commercializing its Telo-MM solution for Multiple Myeloma. She has overseen the collaboration with the Mayo Clinic to validate the Telo-MM tests. Her strategic decisions have centered on expanding the company's product pipeline and securing regulatory approvals. She has also focused on building a strong team and fostering a culture of innovation.
TDSGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Telo Genomics Corp. may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. This tier is generally associated with higher risk and greater potential for fraud compared to companies listed on major exchanges like NYSE or NASDAQ, which have stricter listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of readily available financial information makes it difficult to assess the company's financial health and performance.
- Low Liquidity: The low trading volume and wide bid-ask spreads can make it challenging to buy or sell shares quickly and at desired prices.
- Regulatory Uncertainty: OTC-listed companies are subject to less regulatory oversight than those listed on major exchanges, increasing the risk of fraud and mismanagement.
- Price Volatility: The limited liquidity and speculative nature of OTC stocks can lead to increased price volatility.
- Going Concern Risk: Companies on the OTC Other tier may face a higher risk of financial distress or bankruptcy.
- Verify the company's legal registration and business licenses.
- Review any available financial statements and audit reports.
- Assess the company's management team and their track record.
- Investigate the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Consult with a financial advisor to assess the risks and potential rewards.
- Check for any regulatory actions or legal disputes involving the company.
- Collaboration with the Mayo Clinic provides some validation of the company's technology.
- Focus on a specific niche market (Multiple Myeloma diagnostics).
- Presence of a CEO with relevant experience in the biotech industry.
- Company has been in operation since 2014.
- Development of a proprietary software platform (TeloView).
Common Questions About TDSGF (Healthcare)
What does Telo Genomics Corp. do?
Telo Genomics Corp. is a biotech company focused on developing and commercializing predictive diagnostic solutions, primarily centered around its telomere analysis platform. Their flagship product, Telo-MM, is designed to provide actionable information to medical professionals in the treatment of Multiple Myeloma, a type of blood cancer. The company also offers TeloView, a proprietary software platform used to quantify specific features of a patient's telomeres. Telo Genomics serves pathologists, clinicians, academic researchers, and drug developers, aiming to personalize treatment plans and improve patient outcomes through advanced diagnostic technologies.
What are the main risks for TDSGF?
Telo Genomics Corp. faces several risks, including competition from larger, more established diagnostic companies, regulatory hurdles and approval delays, and the potential for technological obsolescence. As a small company with limited resources, TDSGF may struggle to compete effectively in the market. The company's OTC listing introduces liquidity and regulatory risks, making it more difficult for investors to buy or sell shares. Dependence on a single lead product (Telo-MM) also poses a risk, as any setbacks in its development or commercialization could significantly impact the company's financial performance. Investors should carefully consider these risks before investing in TDSGF.
What are the key factors to evaluate for TDSGF?
Evaluate TDSGF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does TDSGF data refresh on this page?
TDSGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TDSGF's recent stock price performance?
Telo Genomics Corp. (TDSGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary telomere analysis technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TDSGF overvalued or undervalued right now?
Valuing Telo Genomics Corp. (TDSGF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TDSGF?
Before investing in Telo Genomics Corp. (TDSGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding TDSGF to a portfolio?
Key strength of Telo Genomics Corp. (TDSGF): Proprietary telomere analysis technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis is pending and may provide further insights.